rhErythropoietin in Cancer Supportive Treatment

The significance of anaemia in cancer patients: progress in understanding haematopoiesis; pathophysiology of cancer-related anaemia; the incidence and clinical significance of anaemia in malignant diseases; the cost-effectiveness of rhEPO use in anaemia of cancer; problems of blood transfusion specific to cancer patients: problems of providing a national blood-transfusion service; the effect of blood donation on prognosis and infectious complications after colorectal cancer surgery; the effects of allogenic and autologous blood transfusions on the prognosis of cancer patients; clinical efficacy and safety of rhErythropoietin in cancer patients: rhEPO treatment for the anaemia of multiple myelo-ma and non-Hodgkin's lymphoma; controlled mul-ticentre study on the influence of two different Dos-ages of subcutaneous rhEPO on the development of anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based combination chemotherapy; rhEPO in the treatment of anaemia associated with malignancy; the use of rhEPO for the prevention and treatment of cytostatics-induced anaemia in children; predictors of response to rhEPO in non-renal anaemia; experimental data concerning the safety profile of rhEPO in the treatment of cancer patients; a meta-analysis on the safety of epoietin-B therapy in cancer patients; potential use of rhErythropoietin in haematopoietic stem-cell disorders: rhEPO in the treatment of the myelo-dysplastic syndromes; rhEPO in combination with other growth factors in haematological malignancies; tudor oxygenation in cancer therapy: tudor oxygenation - characterization and clinical implications; tudor oxygenation - is it important? can it be improved?